An integrated approach to biodistribution radiation absorbed dose estimates

Noz, Marilyn E.; Kramer, Elissa L.; Maguire, Gerald Q.; McGee, Sharon A.; Sanger, Joseph J.

doi:10.1007/bf00168878

Cited by 7 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The growing use of radionuclide therapy justifies a dedicated treatment planning system. Noz et al (1993) has described a program whereby a user-friendly approach is pursued to extract biodistribution data and estimate the dose of radiation absorbed using the MIRD formalism. A 'point and click' user-interface approach has been described by Johnson (1988) for MABDOSE, by Stabin (1996) for MIRDOSE3 and by Erdi et al (1994a) for GWRIT.…”

Section: Treatment Planningmentioning

confidence: 99%

Treatment planning for radio-immunotherapy

Erdi¹,

Erdi

Yorke

et al. 1996

Phys. Med. Biol.

View full text Add to dashboard Cite

To foster the success of clinical trials in radio-immunotherapy (RIT), one needs to determine (i) the quantity and spatial distribution of the administered radionuclide carrier in the patient over time, (ii) the absorbed dose in the tumour sites and critical organs based on this distribution and (iii) the volume of tumour mass(es) and normal organs from computerized tomography or magnetic resonance imaging and appropriately correlated with nuclear medicine imaging techniques (such as planar, single-photon emission computerized tomography or positron-emission tomography). Treatment planning for RIT has become an important tool in predicting the relative benefit of therapy based on individualized dosimetry as derived from diagnostic, pre-therapy administration of the radiolabelled antibody. This allows the investigator to pre-select those patients who have 'favorable' dosimetry characteristics (high time-averaged target: non-target ratios) so that the chances for treatment success may be more accurately quantified before placing the patient at risk for treatment-related organ toxicities. The future prospects for RIT treatment planning may yield a more accurate correlation of response and critical organ toxicity with computed absorbed dose, and the compilation of dose-volume histogram information for tumour(s) and normal organ(s) such that computing tumour control probabilities and normal tissue complication probabilities becomes possible for heterogeneous distributions of the radiolabelled antibody. Additionally, radiobiological consequences of depositing absorbed doses from exponentially decaying sources must be factored into the interpretation when trying to compute the effects of standard external beam isodose display patterns combined with those associated with RIT.

show abstract

Section: Treatment Planningmentioning

confidence: 99%

Treatment planning for radio-immunotherapy

Erdi¹,

Erdi

Yorke

et al. 1996

Phys. Med. Biol.

View full text Add to dashboard Cite

show abstract

“…For both qsh and DX the user interface has been standardized through implementation of the MIT Xli Window System with the Open Software Foundation's Motif graphical user environment. (12,13) Motif provides a "point and click" menu system eliminating the need to remember individual commands. Additionally, Motif and Xii are provided as standard software on all UNIX platforms including SUN's.…”

Section: Computer Systemmentioning

confidence: 99%

<title>Quantitative 3D visualization in nuclear medicine</title>

et al. 1995

Self Cite

View full text Add to dashboard Cite

SPECT is a powerful clinical tool. However, the low spatial resolution and ill-defined boundaries associated with SPECT require special consideration in visualization. Quantitative geometric and magnitude information are areas of particular usefulness in evaluating disease states. In this paper, we describe a set of practical 3D visualization tools to display and analyze SPECT data, and present interactive methods to measure (i) the relative position, size and shape of regions of interest and (ii) the magnitude and distribution of radioactive count information. Interactive pick tools allow users to extract values at selected points, distance between points, or value profiles along selected line segments. In the three-dimensional reconstruction, transparent and opaque isosurfaces are formed simultaneously at specified activity levels, and the volume enclosed by the opaque surface is displayed. The utility of these tools is demonstrated with two types of patient studies: those using tumor-avid agents to identify active tumor in the chest and abdomen, and those used for evaluating the volume of perfused myocardium.

show abstract

Radioimmunodetection of non-small cell lung cancer using technetium-99m-anticarcinoembryonic antigen immu-4 fab′ fragment

Kramer

Noz

Liebes

et al. 1994

Cancer

View full text Add to dashboard Cite

Background. Although computed tomography and magnetic resonance imaging have improved the staging and evaluation of non‐small cell lung cancer (NSCLC), mediastinal staging lacks adequate specificity and sensitivity. Radioimmunodetection may augment computed tomography and magnetic resonance imaging. The authors evaluated the ability of the technetium 99m‐anticarcino‐embryonic antigen IMMU‐4 Fab′ fragment to localize NSCLC in vivo, measured its pharmacokinetics, and estimated its radiation dose. Methods. Seventeen patients with carcinoembryonic antigen‐positive NSCLC received 16–30 mCi of technetium 99m IMMU‐4 Fab′. Planar imaging was performed at 1–7 hours and 20–24 hours. Single‐photon emission computed tomography (SPECT) was performed within 8 hours after injection. In 10 patients, blood sampling, urine collection, and quantitative imaging were performed to determine blood and urine pharmacokinetics and radiation dose estimates. Human anti‐mouse antibody response was measured for as long as 3 months after administration. Results. Planar and/or SPECT imaging detected 72% of 32 known lesions. SPECT was more sensitive than planar imaging. T½ohα averaged 0.18 ± 0.33 hours; T½ohβ averaged 8.02 ± 5.53 hours. The mean concentration versus time value was 1.11 ± 0.56 mg.h. The average whole body dose estimated for administration of 30 mCi was 0.45 ± 0.08 rads. No human anti‐mouse antibody responses were detected. Conclusion. The tumor detection rate was high, but the persistent blood pool at < 8 hours complicated image interpretation. An intermediate imaging time point (12–16 hours) might be preferable. SPECT is an important adjunct to imaging with this radioimmunoconjugate. The acceptable dosimetry estimated for 30 mCi Technetium 99m IMMU‐4 Fab′ and the lack of human anti‐mouse antibody responses suggest this is a promising localizing tool for NSCLC. Cancer 1994; 73:890–5.

show abstract

An integrated approach to biodistribution radiation absorbed dose estimates

Cited by 7 publications

References 8 publications

Treatment planning for radio-immunotherapy

Treatment planning for radio-immunotherapy

<title>Quantitative 3D visualization in nuclear medicine</title>

Radioimmunodetection of non-small cell lung cancer using technetium-99m-anticarcinoembryonic antigen immu-4 fab′ fragment

Contact Info

Product

Resources

About